Latest Breaking News On - Josea plaza - Page 1 : vimarsana.com

Many melanoma patients could avoid the risk for toxicity from combination therapies, study suggests

Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.

United statesDavid wadaEmily hendersonAlexandra ikeguchiGaryc doolittleElad sharonNikhili khushalaniSapnap patelKari kendraKatiem campbellAntoni ribasJoseph markowitzZeynep erogluArthurg jamesJosea plazaToni roberts

High Response Rate to Pembrolizumab in Unresectable Desmoplastic Melanoma Trial

High Response Rate to Pembrolizumab in Unresectable Desmoplastic Melanoma Trial
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesSaint michaelKari kendraDavid wadaJohn hyngstromZeynep erogluAntoni ribasJeffreya sosmanMichaelc wuGeorge negreaKatiem campbellNikhil khushalaniAndrew brohlToni robertsArthurg jamesAlexandra ikeguchi

Immunotherapy Shows Exceptional Response Rates in Melanoma Patients

Immunotherapy Shows Exceptional Response Rates in Melanoma Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesOhio state universityKatiem campbellSapnap patelMichaelc wuGeorge negreaJeffrey sosmanZeynep erogluAntoni ribasJohn hyngstromKari kendraDavid wadaShay bellaseaJoseph markowitzSamer kasbariNikhili khushalani

SWOG S1512 trial sees high response rate to p

Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after treatment with the immunotherapy drug pembrolizumab in a recent clinical trial. These results from the S1512 trial are being delivered in an oral presentation at the clinical trials plenary session of the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, on April 16th.

Saint michaelUnited statesMichaelc wuGeorge negreaJosea plazaKatiem campbellJeffreya sosmanAntoni ribasGaryc doolittleKari kendraAndrew brohlNikhil khushalaniZeynep erogluAlexandra ikeguchiSamer kasbariToni roberts